Chong Chyn Chua

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri et al. · Blood · 2020 · 628 citations · Full text

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Chong Chyn Chua, Andrew W. Roberts, John Reynolds et al. · Journal of Clinical Oncology · 2020 · 183 citations

Immunology, Pharmacotherapy, Tumor Biology +18

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Donia M. Moujalled, Fiona C. Brown, Chong Chyn Chua et al. · Blood · 2022 · 95 citations · Full text

Hematological Malignancy, Bax Confer Resistance, Medicine +14

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Uma Borate, Jordi Esteve, Kimmo Porkka et al. · Blood · 2019 · 85 citations

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Chong Chyn Chua, Danielle Hammond, Andrew Kent et al. · Blood Advances · 2022 · 58 citations · Full text